SynthesisScientific reports2017
Leukemia and Risk of Venous Thromboembolism: A Meta-analysis and Systematic Review of 144 Studies Comprising 162,126 Patients.
Synthesis in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review.Oncology · 2026Pooled it
- Anticoagulants in hematologic malignancies: what is the data?Hematology. American Society of Hematology. Education Program · 2025Review
- Trends and Predictors of Venous Thromboembolism and Major Hemorrhagic Events in Hospitalized Leukemia Patients: A Cross-Sectional Analysis of the NIS (2016-2020).Clinics and practice · 2025Article
- Acute heart failure in patients with hematologic malignancies: A nationwide analysis 2016-2021.SAGE open medicine · 2025Article
- Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients.Bone marrow transplantation · 2023Article
- Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- A Massive Right Atrial Mass in Chronic Myelogenous Leukaemia: A Case Report and Literature Review.European journal of case reports in internal medicine · 2022Article
- Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts.Cancers · 2021Article
- Soluble P-selectin and correlation with Prothrombin Fragment 1 + 2 in myeloid malignancies in Cipto Mangunkusumo general hospital.Thrombosis journal · 2021Article
- Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality.TH open : companion journal to thrombosis and haemostasis · 2020Article
- Neutrophils: back in the thrombosis spotlight.Blood · 2019Review
- Acute lymphoblastic leukemia presenting with mesenteric ischemia.Gastroenterology and hepatology from bed to bench · 2019Article
- Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience.Thrombosis journal · 2019Article
- Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia.Thrombosis research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) has significant clinical implications in leukemia patients. However, the actual frequency of this complication remains unknown. We performed a systematic review and meta-analysis to better estimate the frequency of this complication and to assess the risk factors that contribute to its occurrence. We searched several databases, including PubMed, Embase, and Web of Science, and assessed study quality using the Newcastle-Ottawa scale. The pooled frequency of VTE in leukemia patients was calculated. A total of 144 studies met the eligibility criteria. The incidence rate (IR) of VTE from 72 prospective studies comprising 9,061 patients was 5% (95%CI: 4-6%). The incidence rate (IR) of VTE in ALL, CLL, total-AML, and CML population was 5% (95%CI: 4-6%), 3% (95%CI: 2-5%), 6% (95%CI: 4-8%) and 13% (95%CI: 1-36%). The incidence of VTE was markedly decreased among ALL patients who received anticoagulation treatment (IR: 1%, 95%CI: 0-6%) or concentrates therapy (IR: 3%, 95%CI: 0-9%). The overall incidence of VTE in the leukemia population was high, particularly in transplant recipients, who had the highest risk (IR: 8%, 95% CI: 4-13%). Prophylactic approaches could significantly decrease the occurrence of VTE events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.